David Coldiron Joins CMTA Board of Directors

The Charcot-Marie-Tooth Association (CMTA), the national patient advocacy organization leading CMT research, today announced the appointment of David Coldiron to its Board of Directors.

New Gene Therapy Development Program for CMT2A

Passage Bio, a genetic medicines company developing AAV-delivered gene therapies, today announced a gene therapy development program for Charcot-Marie-Tooth Neuropathy Type 2A (CMT2A).

Frequently Asked Questions: Ionis/CMTA 1A Research Announcement

What is CMT1A? Type1ACMT1A is the most common form of

CMT1A Research Breakthrough!

A paper published December 4th on the Journal of Clinical

CMT1A Ionis Press Release

 New Research Shows Promise for CMT Progressive Neuromuscular Disease Potential